Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-9560
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’ ; volume:14 ; number:1 ; day:23 ; month:5 ; year:2016 ; pages:1-2 ; date:12.2016
Thrombosis journal ; 14, Heft 1 (23.5.2016), 1-2, 12.2016
- Creator
-
Yamada, Norikazu
- Contributor
-
Hirayama, Atsushi
Maeda, Hideaki
Sakagami, Satoru
Shikata, Hiroo
Prins, Martin H.
Lensing, Anthonie W. A.
Katō, Masaharu
Onuma, Junichi
Miyamoto, Yuki
Iekushi, Kazuma
Kajikawa, Mariko
SpringerLink (Online service)
- DOI
-
10.1186/s12959-016-0085-1
- URN
-
urn:nbn:de:1111-201605257895
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yamada, Norikazu
- Hirayama, Atsushi
- Maeda, Hideaki
- Sakagami, Satoru
- Shikata, Hiroo
- Prins, Martin H.
- Lensing, Anthonie W. A.
- Katō, Masaharu
- Onuma, Junichi
- Miyamoto, Yuki
- Iekushi, Kazuma
- Kajikawa, Mariko
- SpringerLink (Online service)
Other Objects (12)
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
Venous anomalies and thromboembolism
Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
Venous anomalies and thromboembolism
Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
Venous anomalies and thromboembolism
Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding